/THOXF
THOXF Stock - BioPorto A/S
Healthcare|Medical - Diagnostics & ResearchOTC
$0.29+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for THOXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.29 – $0.29
TARGET (TP)$0.33
STOP LOSS$0.26
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.31
52W High$0.31
52W Low$0.29
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $36.24M | $30.96M | $28.97M | $24.25M | $23.20M |
| Gross Profit | $24.53M | $20.18M | $19.04M | $15.04M | $13.34M |
| Gross Margin | 67.7% | 65.2% | 65.7% | 62.0% | 57.5% |
| Operating Income | $-75,452,000 | $-61,172,000 | $-78,944,000 | $-65,255,000 | $-63,590,000 |
| Net Income | $-68,243,000 | $-56,328,000 | $-75,923,000 | $-57,113,000 | $-61,562,000 |
| Net Margin | -188.3% | -181.9% | -262.1% | -235.5% | -265.3% |
| EPS | $-0.17 | $-0.16 | $-0.23 | $-0.21 | $-0.29 |
Company Overview
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
THOXFBeat Rate
53%
Last 17 quarters
Avg Surprise
-60.3%
EPS vs Estimate
Beats / Misses
9/7
1 met exactly
Latest EPS
$-0.04
Q3 2025
EPS Surprise History
Q3 23
+36.9%
$-0.00vs$-0.01
Q1 24
No data
Q2 24
-15.5%
$-0.01vs$-0.00
Q3 24
-38.4%
$-0.01vs$-0.00
Q4 24
+4.2%
$-0.01vs$-0.01
Q1 25
+24.3%
$-0.01vs$-0.01
Q2 25
-782.7%
$-0.06vs$-0.01
Q3 25
-411.7%
$-0.04vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.01 | — | — | — |
Q3 2025 | Aug 15, 2025 | $-0.01 | $-0.04 | -411.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.01 | $-0.06 | -782.7% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.01 | $-0.01 | +24.3% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.01 | $-0.01 | +4.2% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-0.00 | $-0.01 | -38.4% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.00 | $-0.01 | -15.5% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | — | $-0.00 | — | — |
Q3 2023 | Sep 30, 2023 | $-0.01 | $-0.00 | +36.9% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.01 | $-0.01 | -15.7% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.01 | $-0.01 | -0.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q3 2022 | Aug 17, 2022 | $-0.05 | $-0.05 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q2 2022 | Apr 6, 2022 | $-0.06 | $-0.01 | +84.1% | ✓ BEAT |
Q4 2021 | Nov 17, 2021 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q3 2021 | Aug 18, 2021 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about THOXF
What is THOXF's current stock price?
BioPorto A/S (THOXF) is currently trading at $0.29 per share. The stock has moved +0.00% today.
What is the analyst price target for THOXF?
No analyst price targets are currently available for this stock.
What sector is BioPorto A/S in?
BioPorto A/S operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the OTC exchange.
What is THOXF's market cap?
BioPorto A/S has a market capitalization of $0.13 billion, making it a small-cap company.
Does THOXF pay dividends?
No, BioPorto A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLVLF
Clinuvel Pharmaceuticals Limited
$7.70
Mkt Cap: $0.4B
COGZF
Cogstate Limited
$1.43
Mkt Cap: $0.2B
CYDY
CytoDyn Inc.
$0.28
Mkt Cap: $0.4B
EAPIF
Euroapi S.A.
$2.63
Mkt Cap: $0.3B
EDTXF
Spectral Medical Inc.
$0.90
Mkt Cap: $0.3B
IDGXF
Integrated Diagnostics Holdings plc
$0.68
Mkt Cap: $0.4B
IOBCF
Ion Beam Applications S.A.
$13.25
Mkt Cap: $0.4B
NWBO
Northwest Biotherapeutics, Inc.
$0.25
Mkt Cap: $0.4B
ONVVF
Oneview Healthcare PLC
$0.16
Mkt Cap: $0.1B
PRRUF
Immutep Limited
$0.27
Mkt Cap: $0.4B
Explore stocks similar to THOXF for comparison